News

A judge has denied Tallahassee City Commissioner Jeremy Matlow's request to have his lawsuit against the Blueprint Intergovernmental Agency board reheard. Circuit Judge John Cooper threw out ...
Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...
We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top ...
Sanofi is paying $129 per share in cash for Blueprint, amounting to a $9.1 billion equity value and a 27% premium on the biotech’s closing price on Friday.
Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US ...
The Generator Blueprint is located in chapter 4 of Nikke’s story campaign, Bouquet. You’ll want to head to the very top corner of the map, and look for a jagged corner just to the left edge.
While Blueprint’s shares jumped by 26% on Monday, Sanofi’s dropped by less than 1%. It is Sanofi’s largest acquisition since its 2018 buyout of hemophilia specialist Bioverativ for $11.8 ...
In the realm where financial acumen blends with personal legacy planning, strategic philanthropy is offering the blueprint for modern wealth management. Today's billionaire donors are engraving ...
Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 billion. Blueprint specializes in systemic mastocytosis and other ...
Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline The deal is Sanofi’s third acquisition so far this year, and executives signaled that more acquisitions could follow By ...
France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European ...
He believes the Blueprint will be further adjusted during next year’s legislative session in 2026. But only slightly. He says the big changes will come in 2027 after next year’s mid-term ...